Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RYPNX | 19.60 | 0.20 | +1.03% |
| Royce Small-Cap Opportunity Invmt | |||
| VLCAX | 176.45 | N/A | N/A |
| Vanguard MStar Large Cap Index Admiral | |||
| MDVYX | 9.87 | N/A | N/A |
| MassMutual Diversified Value Svc | |||
| GGINX | 13.52 | N/A | N/A |
| Goldman Sachs Global Infras Inv | |||
| JPVRX | 23.72 | N/A | N/A |
| JPMorgan Developed International ValueR5 | |||
A.I.dvisor indicates that over the last year, CADL has been loosely correlated with RXRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To CADL | 1D Price Change % | ||
|---|---|---|---|---|
| CADL | 100% | -6.93% | ||
| RXRX - CADL | 45% Loosely correlated | +1.27% | ||
| EDIT - CADL | 45% Loosely correlated | +1.89% | ||
| FDMT - CADL | 43% Loosely correlated | -2.37% | ||
| VIR - CADL | 43% Loosely correlated | +0.38% | ||
| SANA - CADL | 42% Loosely correlated | +1.29% | ||
More | ||||
CADL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 40 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CADL as a result. In 89 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
CADL moved below its 50-day moving average on September 11, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The RSI Indicator entered the oversold zone -- be on the watch for CADL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 98 of 114 cases where CADL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.398) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.